ArticleCureus2026
Thyroid Function Tests and Serum Amylase Levels in Chronic Kidney Disease: A Cross-Sectional Study Correlating Biochemical Changes With Disease Severity at a Tertiary Care Centre in India.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic kidney disease (CKD) represents a major and growing health concern in both global and Indian populations. In addition to progressive renal dysfunction, CKD is frequently accompanied by metabolic and endocrine disturbances that may affect disease progression and patient outcomes. Alterations in thyroid hormone and serum amylase levels are frequently encountered in CKD patients, even in the absence of overt thyroid or pancreatic disease, and may hold important diagnostic and prognostic relevance.
aimThe aim of this study was to evaluate thyroid function parameters (free triiodothyronine (FT3), free thyroxine (FT4), thyroid-stimulating hormone (TSH)) and serum amylase levels in patients with CKD, and to assess their association with disease severity.
methodsThis hospital-based cross-sectional observational study was conducted at a tertiary care centre in India. Adult patients with CKD were classified into stages G1-G5 based on estimated glomerular filtration rate (eGFR). Thyroid function tests were measured using chemiluminescent immunoassay, while serum amylase was estimated by enzymatic colorimetric methods. Statistical analyses were performed to compare biochemical parameters across CKD stages and to evaluate correlations with renal function.
resultsSignificant differences were observed in FT3 and FT4 levels across CKD stages (p=0.010 and p=0.003, respectively), with lower values in advanced stages. TSH levels showed a significant increasing trend across stages (p=0.029). Serum amylase levels demonstrated a rising trend in advanced CKD; however, the difference did not reach statistical significance (p=0.12). Conclusion: Thyroid dysfunction and alterations in serum amylase levels are common findings in patients with CKD and show meaningful associations with disease severity. Incorporating endocrine and enzymatic evaluation alongside conventional renal markers may provide additional clinical insight in the evaluation of patients with CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.